S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Twist Bioscience Stock Forecast, Price & News

-9.93 (-10.90%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.03 million shs
Average Volume
664,653 shs
Market Capitalization
$4.03 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TWST News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Twist Bioscience logo

About Twist Bioscience

Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The firm also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. The company was founded by William Marine Banyai, Emily Marine Leproust and Bill James Peck in February 2013 and is headquartered in San Francisco, CA.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$90.10 million
Book Value
$7.53 per share


Net Income
$-139.93 million
Net Margins
Pretax Margin




Free Float
Market Cap
$4.03 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.14 out of 5 stars

Medical Sector

459th out of 1,388 stocks

Biological Products, Except Diagnostic Industry

72nd out of 202 stocks

Analyst Opinion: 3.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

Is Twist Bioscience a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Twist Bioscience stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TWST, but not buy additional shares or sell existing shares.
View analyst ratings for Twist Bioscience
or view top-rated stocks.

How has Twist Bioscience's stock price been impacted by COVID-19 (Coronavirus)?

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TWST shares have increased by 187.7% and is now trading at $81.14.
View which stocks have been most impacted by COVID-19

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Twist Bioscience

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) issued its quarterly earnings data on Monday, November, 22nd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.80) by $0.04. The firm earned $37.95 million during the quarter, compared to analysts' expectations of $36.26 million. Twist Bioscience had a negative net margin of 106.59% and a negative trailing twelve-month return on equity of 24.59%. The firm's revenue for the quarter was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.54) EPS.
View Twist Bioscience's earnings history

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience issued an update on its first quarter 2022 earnings guidance on Monday, November, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $37 million-$39 million, compared to the consensus revenue estimate of $38.78 million.

What price target have analysts set for TWST?

5 equities research analysts have issued 12 month price objectives for Twist Bioscience's stock. Their forecasts range from $100.00 to $150.00. On average, they anticipate Twist Bioscience's stock price to reach $118.25 in the next year. This suggests a possible upside of 45.7% from the stock's current price.
View analysts' price targets for Twist Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the following people:
  • Emily Marine Leproust, Chairman, President & Chief Executive Officer
  • Patrick Weiss, Chief Operating Officer (LinkedIn Profile)
  • James M. Thorburn, Chief Financial Officer
  • Siyuan Chen, Chief Technology Officer
  • Aaron K. Sato, Chief Scientific Officer

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience CEO Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among Twist Bioscience's employees.

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

When did Twist Bioscience IPO?

(TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital World Investors (8.80%), BlackRock Inc. (8.15%), Sumitomo Mitsui Trust Holdings Inc. (4.35%), Nikko Asset Management Americas Inc. (4.35%), Invesco Ltd. (3.59%) and Allianz Asset Management GmbH (3.51%). Company insiders that own Twist Bioscience stock include Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends for Twist Bioscience

Which institutional investors are selling Twist Bioscience stock?

TWST stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Capital World Investors, Invesco Ltd., Morgan Stanley, Voloridge Investment Management LLC, Marshall Wace LLP, and Cubist Systematic Strategies LLC. Company insiders that have sold Twist Bioscience company stock in the last year include Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess, and William Banyai.
View insider buying and selling activity for Twist Bioscience
or view top insider-selling stocks.

Which institutional investors are buying Twist Bioscience stock?

TWST stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Massachusetts Financial Services Co. MA, BlackRock Inc., Blue Water Life Science Advisors LLC, Dimensional Fund Advisors LP, Allianz Asset Management GmbH, Geode Capital Management LLC, and Macquarie Group Ltd..
View insider buying and selling activity for Twist Bioscience
or or view top insider-buying stocks.

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $81.14.

How much money does Twist Bioscience make?

Twist Bioscience has a market capitalization of $4.03 billion and generates $90.10 million in revenue each year. The company earns $-139.93 million in net income (profit) each year or ($2.86) on an earnings per share basis.

How many employees does Twist Bioscience have?

Twist Bioscience employs 525 workers across the globe.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is www.twistbioscience.com.

Where are Twist Bioscience's headquarters?

Twist Bioscience is headquartered at 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (800) 719-0671 or via email at [email protected].

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.